/stocks — the workspaceLOADING
All PCRX SEC filings, by type → · Earnings date & implied move · Search inside filings
Pacira BioSciences, Inc. (PCRX) is a pharmaceutical preparations company. Piotroski F-Score 7/8. 2 insider Form 4 filings in the last 90 days. Next earnings confirmed for 2026-11-05 (SEC filing). Fundamentals from SEC filings; prices are end-of-day.
What’s behind PCRX’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from PCRX’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on PCRX plus an auto-SWOT — built from PCRX's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate PCRX using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has PCRX been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
This date and time was extracted directly from PCRX's own Form 8-K (earnings press release) filed with the U.S. Securities and Exchange Commission — not an analyst estimate or a third-party calendar. We mark a report “confirmed” only when the company itself has stated the date in a public SEC filing, and we link that filing above so you can verify it. Everything else stays an honest estimate from the company's filing cadence. From filings, not guesses.
Projected from PCRX's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentPCRX files or announces.
PCRX has sold off after 6 of its last 8 earnings reports.
Each figure is one earnings reaction — how much PCRX moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Earnings reactions have been moderate.
PCRX has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+2.4% and -7.6%).
A more typical earnings reaction has been approximately ±2.6%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-04 | -7.6% |
| 2026-04-30 | -2.8% |
| 2026-02-26 | -6.6% |
| 2025-11-06 | +0.9% |
| 2025-08-05 | -2.4% |
| 2025-05-08 | -0.2% |
| 2025-02-27 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -5.6% |
| 2024-11-06 | +2.4% |
No lawmaker has disclosed a trade in PCRX under the STOCK Act.
No tracked institution reported a position in PCRX in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| IJR iShares Core S&P Small-Cap ETF | 0.05% | 2026-06-30 |
| IWM iShares Russell 2000 ETF | 0.03% | 2026-06-30 |
| ITOT iShares Core S&P Total US Stock Market ETF | <0.01% | 2026-06-30 |
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Shareholder returns exceeded free cash flow this period — the difference was funded from cash on hand, debt, or asset sales rather than the business itself. Common and sustainable for a period; worth watching if it persists.
Every figure is from PCRX’s SEC cash-flow statement. This describes how management deployed cash last period — it is not a grade of that deployment, not a forecast, and not investment advice. Whether reinvesting, paying down debt, or returning cash was the right call depends on the return each earns, which the filings do not settle. Educational information only.
Head office: Brisbane, California, United States · the company’s charter and its head office are in different states.
Source: the cover page of Pacira BioSciences, Inc.’s 10-Q filed 2026-08-04, on EDGAR. Filings checked 2026-10-16. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
| RIKER LAURENSenior Vice President, Finance | SELL | $218K | view → |
| SLONIN JONATHANChief Medical Officer | SELL | $71K | view → |
| RIKER LAURENSenior Vice President, Finance | SELL | $144K | view → |
| WILLIAMS KRISTENChief Administrative Officer | SELL | $228K | view → |
| Cross ShawnChief Financial Officer | SELL | $326K | view → |
| Cross ShawnChief Financial Officer | SELL | $303K | view → |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.